Aptevo Therapeutics Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for APVO, updated each market day.
APVO AI Sentiment
AI sees no strong directional signal for Aptevo Therapeutics Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Sector
Exchange
Market Cap
$5,164,138
Cap Tier
Employees
33
Headquarters
SEATTLE, WA
Listed Since
July 20, 2016
APVO Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
APVO Volatility
Aptevo Therapeutics Inc has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
